Sequential bilateral lung transplantation for pulmonary alveolar microlithiasis

Stamatis, G; Zerkowski, Hans‐Reinhard; Doetsch, N.; Greschuchna, D; Konietzko, N.; Reidemeister, J. Chr.

doi:10.1016/0003-4975(93)90370-w

Cited by 58 publications

(30 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, two patients underwent single lung transplantation with acceptable results, and thus far have shown no evidence of recurrence in the transplanted lung [64,67]. Furthermore, even after bilateral transplantation it is not known whether PAM can recur.…”

Section: Therapy and Lung Transplantationmentioning

confidence: 99%

“…In 1988, the Toronto Lung Transplantation Group reported a successful double lung transplantation in humans. The first bilateral lung transplant in a patient with PAM was described in 1992 in France [63], followed by a second one in 1993 in Germany [64] and two others in 1997 in the USA [65]. Single transplants were reported in 1996 in Saudi Arabia [66], in 2001 in Canada [67], in 2009 in Iran [68] and in 2014 in Italy [69].…”

Section: Therapy and Lung Transplantationmentioning

confidence: 99%

See 1 more Smart Citation

Pulmonary alveolar microlithiasis: review of the 1022 cases reported worldwide

et al. 2015

View full text Add to dashboard Cite

Pulmonary alveolar microlithiasis (PAM) is a rare disease characterised by the widespread intra-alveolar accumulation of minute calculi called microliths. It is caused by mutation of the SLC34A2 gene encoding the type IIb sodium phosphate cotransporter in alveolar type II cells. The present study explores the epidemiological, familial, genetic, clinical, diagnostic, radiological and therapeutic aspects with the aim of contributing to a better understanding of this uncommon disease.We searched articles on PAM published up to December 2014 and 544 papers were found, accounting for 1022 cases.PAM is present in all continents and in many nations, in particular in Turkey, China, Japan, India, Italy and the USA. Familiality is frequent. The clinical course is not uniform and the causes of this clinical variability seem to be largely nongenetic. The optimal diagnostic procedure is the association of chest high-resolution computed tomography (HRCT) with bronchoalveolar lavage, but a chest radiograph may suffice in families in which a case has already been diagnosed. Moreover, chest radiography and HRCT allow the classification of the evolutionary phase of the disease and its severity. At present lung transplantation is the only effective therapy. However, better knowledge of the gene responsible offers hope for new therapies. @ERSpublications Familial, genetic, clinical, radiological and therapeutic aspects of pulmonary alveolar microlithiasis epidemiology http://ow.ly/St3Mw

show abstract

Section: Therapy and Lung Transplantationmentioning

confidence: 99%

Section: Therapy and Lung Transplantationmentioning

confidence: 99%

Pulmonary alveolar microlithiasis: review of the 1022 cases reported worldwide

et al. 2015

View full text Add to dashboard Cite

show abstract

“…transplantations instead of unilateral transplants on the grounds of resistant shunt development in a lung transplantation series of 14 cases, one of which was caused by PAM 12 . Besides, no recurrence was detected in the presented cases or series 7,8,10,13,14 . Moon et al reported the case of a patient who survived for 15 postoperative years with no recurrence after the lung transplantation was performed after PAM diagnosis 8 .…”

Section: Discussionmentioning

confidence: 52%

Lung transplantation in an intensive care patient with pulmonary alveolar microlithiasis - a case report

Güçyetmez¹,

Ogan²,

Ayyıldız³

et al. 2014

F1000Res

View full text Add to dashboard Cite

“…3 Disease is prevalent amongst family units with a high rate of consanguinity among the parents of affected individuals suggesting the hypothesis of the role of genetic factors in causing PAM. 9,10,11 Recently, corutctal et al have identified the gene mutation responsible for the disease as SLC34A2 (the type IIb sodium phosphate co-transporter gene), which is involved in phosphate homeostasis in several organs, including the lung surface, readily apparent on HRCT. 12 Asymptomatic cases, even with extensive radiographic involvement, are often discovered incidentally.…”

Section: Discussionmentioning

confidence: 99%